Projections for 2026 indicate the largest single-year increase in employer health costs in 15 years, with an expected rise of ...

One runs healthcare clinics serving rural communities. Another provides legal and shelter services to domestic violence ...

Hensoldt’s stock is now a "Buy" with 15% upside, strong order intake, and sector valuation growth. Here's what investors need ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...